Bicocca Open Archive

Logo unimib boa
CORTINOVIS, DIEGO LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.906
AS - Asia 12.877
EU - Europa 7.773
SA - Sud America 1.796
Continente sconosciuto - Info sul continente non disponibili 961
AF - Africa 261
OC - Oceania 18
Totale 40.592
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.029
SG - Singapore 4.255
IT - Italia 2.866
CN - Cina 2.284
VN - Vietnam 2.121
HK - Hong Kong 1.903
BR - Brasile 1.334
RU - Federazione Russa 1.296
DE - Germania 748
IE - Irlanda 707
BD - Bangladesh 683
CA - Canada 626
SE - Svezia 511
FR - Francia 331
GB - Regno Unito 314
KR - Corea 311
IN - India 295
UA - Ucraina 215
ID - Indonesia 201
FI - Finlandia 179
AR - Argentina 166
AT - Austria 137
NL - Olanda 132
IQ - Iraq 115
TR - Turchia 114
JP - Giappone 100
MX - Messico 96
ZA - Sudafrica 83
SA - Arabia Saudita 78
PK - Pakistan 76
EC - Ecuador 74
CO - Colombia 72
ES - Italia 66
PL - Polonia 60
PH - Filippine 59
VE - Venezuela 49
UZ - Uzbekistan 43
DK - Danimarca 40
JM - Giamaica 35
MA - Marocco 34
MY - Malesia 33
PY - Paraguay 30
CL - Cile 29
BE - Belgio 27
CH - Svizzera 25
JO - Giordania 24
KE - Kenya 24
CR - Costa Rica 23
EG - Egitto 22
AE - Emirati Arabi Uniti 20
LB - Libano 19
NP - Nepal 19
TN - Tunisia 19
ET - Etiopia 18
AL - Albania 17
TT - Trinidad e Tobago 16
AU - Australia 15
PE - Perù 15
TH - Thailandia 15
NI - Nicaragua 14
TW - Taiwan 14
UY - Uruguay 14
CZ - Repubblica Ceca 13
HN - Honduras 12
KZ - Kazakistan 12
AZ - Azerbaigian 11
BO - Bolivia 11
DZ - Algeria 11
GR - Grecia 11
OM - Oman 11
DO - Repubblica Dominicana 9
GT - Guatemala 9
PS - Palestinian Territory 9
LT - Lituania 8
BG - Bulgaria 7
IL - Israele 7
IR - Iran 7
SI - Slovenia 7
SN - Senegal 7
SV - El Salvador 7
BB - Barbados 6
BS - Bahamas 6
CI - Costa d'Avorio 6
PR - Porto Rico 6
RO - Romania 6
AO - Angola 5
GA - Gabon 5
HR - Croazia 5
KG - Kirghizistan 5
LU - Lussemburgo 5
RS - Serbia 5
AM - Armenia 4
CG - Congo 4
EE - Estonia 4
EU - Europa 4
GE - Georgia 4
HU - Ungheria 4
KH - Cambogia 4
MK - Macedonia 4
NO - Norvegia 4
Totale 39.555
Salva come PNG Salva come JPEG
Città #
Singapore 2.449
Hong Kong 1.850
Ashburn 1.764
San Jose 1.563
Ann Arbor 1.270
Milan 895
Dublin 686
Ho Chi Minh City 679
Hefei 635
Hanoi 573
Fairfield 533
New York 497
Council Bluffs 468
Toronto 418
Woodbridge 414
Frankfurt am Main 410
Chicago 389
Santa Clara 372
Los Angeles 369
Chandler 361
Wilmington 318
Dallas 292
Seoul 291
The Dalles 287
Houston 263
Rome 262
Seattle 246
Beijing 241
Cambridge 211
Lauterbourg 201
Jacksonville 181
Boardman 153
Princeton 153
Buffalo 151
Jakarta 144
São Paulo 143
Moscow 131
Dearborn 126
Phoenix 122
Shanghai 103
Vienna 97
Turin 95
Helsinki 88
London 86
Columbus 82
Figino 80
Haiphong 73
Nuremberg 69
Orem 69
Lawrence 68
Da Nang 67
Tokyo 67
Munich 61
Brooklyn 59
Altamura 57
Guangzhou 57
Nanjing 54
Atlanta 52
Montreal 51
San Diego 51
Naples 50
Salt Lake City 46
Warsaw 45
Baghdad 44
Denver 44
Rio de Janeiro 44
Lappeenranta 43
San Francisco 41
Tashkent 40
Amsterdam 39
Dhaka 39
Florence 39
Johannesburg 38
Hải Dương 37
Washington 35
Biên Hòa 32
Boston 32
Ha Long 32
Bologna 31
Miami 31
Poplar 31
Lahore 30
Riyadh 30
Tampa 30
Bari 29
Chennai 29
Ninh Bình 29
Kent 28
Mexico City 28
Philadelphia 28
Stockholm 28
Brussels 27
New Delhi 27
Detroit 26
Las Vegas 26
Andover 25
Can Tho 25
Jeddah 25
Lachine 25
Newark 25
Totale 23.330
Salva come PNG Salva come JPEG
Nome #
The ‘Liaisons dangereuses’ Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation 561
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 519
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma 511
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 437
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 432
Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment? 422
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 422
Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases 420
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 396
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 360
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 351
The Association between Vitamin D and Gut Microbiota: A Systematic Review of Human Studies 347
The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT 341
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 326
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 324
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 312
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 311
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 311
Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (Nsclc): A real world experience 311
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 309
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 307
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 302
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer 300
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNoms study 299
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 298
Clinical treatment of cholangiocarcinoma: an updated comprehensive review 297
The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience 294
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 288
Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer 287
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 287
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion 284
Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients 282
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 281
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial 279
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 277
Vitamin D supplementation and cancer mortality: Narrative review of observational studies and clinical trials 273
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 270
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial 267
When progressive dysphagia could be related to an “old friend” – a case report 266
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 261
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 260
RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer 260
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 258
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 255
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 255
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 254
Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis 254
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 250
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial 248
Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer 243
MR309/E-52862, a first-in-class sigma-1 receptor antagonist, in oxaliplatin-induced peripheral neuropathy. An exploratory Phase II clinical trial 240
Novel cytotoxic chemotherapies in small cell lung carcinoma 240
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 237
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer 235
Economic assessment of NGS testing workflow for NSCLC in a healthcare setting 231
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 230
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 225
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 224
MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database 222
Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 221
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer 220
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 220
Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer 219
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 217
Colorectal Cancer Pulmonary Metastasectomy: When, Why and How 216
Novel Therapeutic Options for Small Cell Lung Cancer 216
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials 215
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 215
Pleural mesothelioma in situ: A comprehensive review 211
Time to Next Treatment Following Sub-Ablative Progression Directed Radiation Therapy for Oligoprogressive Non-Small-Cell Lung Cancer 206
Intratumoral Treatment in Lung Cancer: Is It Time to Move Towards Clinical Practice? 206
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons 206
Focus on nivolumab in NSCLC 206
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 206
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 205
Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres 200
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 199
Sneaky Diagnosis of Pleural Malignant Mesothelioma in Thoracic Surgery: All That Glitters Is Not Gold 198
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review 198
VITAMIN D SUPPLEMENTATION MAY IMPROVE COVID-19 PROGNOSIS? EVIDENCE FROM A SYSTEMATIC REVIEW AND META-ANALYSIS 197
ALK determination: Liquid and tissue biopsy. Comparing techniques and effectiveness of alectinib in a controversial clinical case [Determinazione di ALK: Tra biopsia liquida e tissutale. Tecniche a confronto ed efficacia di alectinib in un caso clinico controverso] 192
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04–2016 191
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study 189
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 189
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 186
Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges 185
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma 185
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 182
Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives 177
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 173
The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer 172
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program 171
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 169
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO) 165
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 165
Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) 163
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 161
Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study 160
Newest therapeutic strategies impacting on rarest thoracic malignancies: The clinical case report of biphasic pleural mesothelioma 160
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy 159
Totale 25.934
Salva come PNG Salva come JPEG
Categoria #
all - tutte 131.938
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 131.938
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022703 0 0 0 114 64 77 50 42 55 58 82 161
2022/20231.743 211 504 138 184 112 244 24 117 113 39 43 14
2023/20242.515 45 44 45 64 588 530 444 77 309 57 47 265
2024/20256.752 312 712 289 252 541 217 537 207 656 999 657 1.373
2025/202618.896 2.236 1.681 1.247 1.748 1.810 891 2.609 856 1.384 1.354 1.129 1.951
2026/20275.094 1.169 1.397 2.306 222 0 0 0 0 0 0 0 0
Totale 40.592